Overview A Study of CCX140-B in Subjects With Primary FSGS and Nephrotic Syndrome Status: Unknown status Trial end date: 2021-03-01 Target enrollment: Participant gender: Summary An Open Label, Intra-Subject Dose Escalation Study of CCX140 B in Subjects with Primary FSGS and Nephrotic Syndrome Phase: Phase 2 Details Lead Sponsor: ChemoCentryx